Myrtelle releases interim data from gene therapy trial for Canavan disease

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Myrtelle has published interim results from its Phase 1/2 trial of the investigational gene therapy rAAV-Olig001-ASPA (MYR-101) in Nature Medicine, reporting changes in biomarkers, imaging and functional measures in children with Canavan disease, according to the company.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE